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1. Introduction 
The upper airways symptoms in childhood are the most frequent reasons that make 
children and their parents to seek the doctor’s help. The truth is that the symptoms occur as 
viral infections of the upper airways specially in preschool age children. Up to 30% of 
preschool age children with acute upper airway problems will suffer at least one wheezing 
episode, which brings them to the pediatrician for treatment. (Asher et al., 2006) It means 
that for the first 6 years of life every 3rd child will be treated by bronchodilators, antibiotics 
or even anti-inflammatory therapy such as corticosteroids. 
However, data from hundreds of papers and from our experience as well, shows that it is 
“normal and expected for a healthy child”. What is not expected is more than 3 wheezing 
episodes in early life that coexists with numerous upper airways diseases. (Lemanske et al., 
2005) Children with such a history should be observed more carefully and if the symptoms 
gradually get worse, should be referred to a specialist for further investigations. (Sigurs et 
al. 2000; Sigurs et al., 2005) Frequently, these children are atopic with the family history of 
atopy or some comorbid condition that may confirm the allergic background, even if the 
skin prick tests on aeroallergens remains negative. (Ng Man Kwong et al., 2001) Usually, 
child with recurrent wheezing episodes will be suspected of having childhood asthma and 
successfully treated by antiasthma drugs (inhaled corticosteroids and/or leukotriens 
antagonists) not taking into account her/his recurrent or chronic upper airways problems. 
Despite the lack of severe asthma symptoms in these patients, they still suffer from blocked, 
congested upper airways, runny, itchy nose and eyes, reactive cough and mild wheezy 
episodes particularly during the physical activities. This is the scenario that we are facing in 
our everyday practice and this is the reason for involving the investigation and subsequent 
treatment of the upper airways problem in our work. We cannot expect to solve the 






2. Quality of life and allergic rhinitis (AR) in childhood 
Although it is frequently seen as a mild and intermittent AR is capable of changing and 
disturbing the quality of life of the children, as well as their well-being, learning and 
physical activity. Apparently, the severity, and not necessarily the duration of the AR, has a 
more relevant effect on the quality of life of the patients with AR, with main consequences 
on sleep quality and learning ability. (Juniper et al., 1999) The impact that AR severity had 
on quality of life-sleep, activities of daily living and school performance was more 
significant than was the duration of the disease. (Craig et al., 2004) More than 80% of the 
patients with more severe forms reported impairment in their activities due to the disease, 
compared with only 40% of those with mild forms. Disease-specific questionnaires are the 
instruments most widely used in order to "measure the quality of life". In the case of allergic 
rhinoconjunctivitis, the disease-specific questionnaire most commonly used is the 
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). (Nascimento Silva et al., 2001; 
Santos et al., 2006) It is fundamental to highlight that AR-related physical, psychological and 
social impairments are experienced not only by adults but also by children and adolescents. 
Although adolescents experience problems similar to those of the adults, they present 
greater difficulty in concentrating, particularly on their school work. Younger children, 
however, present a slightly different profile: they feel unhappy and unsatisfied, however, 
they tend to experience less limitation in their activities of daily living and do not exhibit the 
emotional disturbance experienced by adults and adolescents. Our experience in assessment 
of quality of life of children with AR alone or associated with asthma, basically shows 
disturbances in physical domen specially during the pollen season in children suffering 
from hay fever. (Cerovic et al., 2009) It was shown by other authors that quality of life (QOL) 
in individuals with perennial chronic rhinitis was worse in relation to persons with mild to 
moderate asthma. (Bousquet 2008a, 1994b, 1994c) Our results on quality of life in children 
with asthma revealed bad score only for physical activities in children while very bad score 
for parents and very high level of anxiety related to their children’s asthma. (Cerovic et al., 
2009) Our survey didn’t divide patients with asthma and allergic rhinitis from patients with 
only one condition, and definitely children are less susceptible to QOL disturbances 
independently of their real condition. However, untreated and undertreated symptoms of 
allergic rhinitis in children, definitely impair overall quality of life mainly due to persistent 
nasal congestion and subsequent feeling of fatigue, headache, cognitive impairment and 
school problems. (Walker et al., 2007) Nasal congestion has been defined as the most 
troublesome condition since it may affect negatively sleep time, resulting in reduced 
daytime activities and particularly sports involvement that is the most important and 
popular among children and adolescents. (Sundberg et al., 2007; Broide 2007) Occasionally, 
recurrent upper airways diseases and clearly allergic rhinitis are the conditions that precede 
or progress to asthma, while in the other cases these are the causes of worsening of already 
existing asthma symptoms. Both conditions lead to continuous usage of drugs, from 
symptomatic once (decongestive medications, antitussive drugs) to evidence-based 
antiallergic, antiasthmatic drugs. Even more, in children with or without obvious signs of 
complications (otitis media, bronchitis, pneumonia) antibiotics are frequently advised in 
every respiratory episode. Overtreatment of these children exists in all cases of children 
hospitalized due to an acute severe bronchiolitis in the first 12 months of age or hospitalized 
due to repeated acute asthmatic attacks. (Rodić et al., 2006; Radić et al., 2009) So far, not only 
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usual predictive or risk factors for developing asthma should be taken into consideration. 
We suggest the hypothesis that individuals with the early life upper airways problem 
similar to so called “common cold symptoms”, should attract our attention for earlier and 
better investigations in terms of proper diagnosis and treatment as early as possible. 
Basically, the possibility of developing asthma after 6 years of age after having allergic 
rhinitis from 3rd to 6th year of life, has been estimated at about 30% in children (not 
administered allergen specific hyposensitization). (Meltzer 2005; Martinez et al., 1995) In 
real life, detailed investigations (that have to be performed before the decision on 
immunotherapy) in children of preschool ages are difficult due to weak cooperation of a 
child and parents as well. Secondly, the lack of information and standardized protocols on 
allergen specific immunotherapy (ASIT) among pediatricians, allergologists and all relevant 
subspecialties make this situation even more complicated.  
Our aim is to present some numbers on prevalence of allergic rhinitis in childhood and 
some considerations about ASIT in children. Long-term benefits have also been seen with 
the use of immunotherapy, although some patients, especially children, resist the injections 
used in subcutaneous immunotherapy. Recent studies with sublingual immunotherapy 
have indicated that it might be an effective and well-tolerated alternative to immunotherapy 
injections. 
3. Epidemiology of allergic rhinitis in children 
Reference list of the articles dealing with the prevalence and epidemiology of childhood 
atopic diseases, mainly asthma, dermatitis and rhinitis, is extremely long and extended. The 
numbers from thousands of surveys varied from too low to too high, rarely can rely on 
approved methodological and statistical background and cannot deserve enough attention 
for valid conclusions. However, the International Study of Asthma and Allergies (ISAAC) 
Phase Three has valuable power involving 98 countries worldwide and 236 Phase Three 
Centers, in other words around 1 059 053 children of 2 age groups from 236 centres in 98 
countries.(Ait-Khaled et al., 2009) (Obviously, this multicentric, multiethnic, multicultural 
study present “a new and greatly enlarged world map of symptom prevalence”. The 
average prevalence of current symptoms of allergic rhinoconjunctivitis across all centres 
was 14.6% for the 13- to 14-year old children. However, extensive variation in the prevalence 
of diagnosis of allergic rhinitis within regions, countries and centres was observed (values 
range from 1% in India to 45.1% in Paraguay). The highest regional prevalence rates of 
current rhinoconjunctivitis were observed in Africa (18.0%) and Latin America (17.3%) and 
the lowest in Northern and Eastern Europe (9.2%). In each region, there were major 
differences in prevalence between countries. Variation in the prevalence of severe 
rhinoconjunctivitis symptoms was also observed between regions (range 0.4% in Western 
Europe to 2.1% in Africa), and between countries within regions. The prevalence of severe 
rhinoconjunctivitis symptoms was generally the highest (more than 1%) in centres from 
middle and low income countries. These are important and valuable observations that socio-
economic impact of the country and regions have been related to the severity of the AR. In 
the 13- to 14-year age group, the prevalence of current AR was substantially lower in centres 
in low income countries compared with those in high income countries. From the other 
hand, centres in low income countries had an increased prevalence of severe AR related to 






These results are sufficient for conclusion that economic burden of allergic rhinitis 
worldwide is enormous and directly related to high morbidity in countries with poor health 
resources. 
The prevalence rate of allergic rhinitis, asthma and eczema in Serbia has been investigated 
as a part of the ISAAC phase 3. The survey was conducted in five regional centers with 
different geographical and urban characteristics. Around 14000 children were enrolled, aged 
6- to 7-year and 13- to 14- years. Prevalence rate of asthma has been 6,59% in 6- to 7- year 
group and 5,36% in 13- to 14- year group respectively. Prevalence of allergic rhinitis has 
been 7,17% in 6- to 7- year age group while 14,89% in the 13- to 14- year age group. We 
found statistically significant difference between groups. Prevalence of eczema has been 
14,04% in younger and 14,45% in older children. When counted prevalence rate in total we 
found asthma in 5,91%, rhinitis in 11,46% and eczema in 14,27%. From the whole number of 
children around 40% presented repeatedly for upper airway problems, 26% presented at 
least once with symptoms of upper and lower airways simultaneously and 11% more than 4 
times for the both conditions for the last 12 months. It means that expenses only for their 
acute episodes highly cross over the expected annual budget for outpatients clinics. In 
addition, AR is commonly associated with other respiratory diseases, and the cost resulting 
from these comorbidities increases even more the socioeconomic impact of the disease. 
(Zivkovic et al., 2010) Not less important conclusion that we made has been that prevalence 
rate has been higher in urban than rural areas except in certain villages near by large air-
pollutants (power stations and chemical industry). This is the conclusion that leads us to 
multifactorial origin of the rhinitis in childhood and particularly for the youngest ages 
seems to be difficult to distinguish allergic from nonallergic rhinitis. 
Our special clinical interest was association of allergic rhinitis in children and wheezing 
episodes or asthma. The majority of children suffer from both conditions from the early 
childhood. From the infancy they experience waterish nasal discharge or congestion all over 
the year, frequently unrelated to day care respiratory infections. Later in childhood they 
present with wheezing episodes, cough or asthma that deserve more attention and 
investigations. (Brand et al., 2008; Zivkovic et al., 2009) Usually, the allergic background of 
the nasal symptoms has been revealed many years after their occurrence. From our study it 
is evident that delay in diagnosis of asthma is around 4,5 years and of allergic rhinitis more 
than 5,7 years. (Zivkovic Z et al., 2009) Analysing the course of allergic symptoms of upper 
and lower airways we found allergic rhinitis frequently associated with pollen allergy, long-
term usage of medication, unsatisfaction of patient and parents and deterioration of quality 
of life. The important effort in the literature was made in assessment of allergic 
inflammation in children with comorbid conditions in regard of treatment of clinically silent 
forms or inappropriate response on therapy. (Pijnenburg et al., 2005; Arnal et al., 1997) We 
measured exhaled NO in children with asthma and allergic rhinitis, 6 to 16 years of life, in 
September – December 2009. (Zivkovic et al., 2009) Clearly, the higher was fraction of 
exhaled NO, the more symptoms allergic rhinitis we detected in children as well as higher 
levels of nasal eosinophils. In conclusion, we stated importance of follow up of a child with 
asthma and AR through the seasons are mostly valuable since atopic conditions are 
developing in terms of season or years. (Zivkovic et al., 2008) What is the main result of our 
studies and clinical surveys? The AR in children is an early life presenting problem, 
recurrent or persistent during the early childhood, frequently associated with the lower 
airway diseases, over treated or maltreated, and finally completely confusing and disturbing 
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in terms of quality of life of children and their families. So far, the various aspects of 
treatments might be successful but over time they become bothersome and hardly 
acceptable for young persons and adolescents. Obviously, we are looking for efficient, easy 
to use and inexpensive treatment, but it is probably not possible. (Mçsges et al., 2007) 
Therefore, we were searching through the literature and clinical practice for the benefits of 
the allergen specific immunotherapy, particularly sublingual immunotherapy (SLIT) as the 
causative way of treatment and would like to present in the other part some of our findings 
and comments. 
SLIT is widely known as an effective treatment for children requiring immunotherapy who 
normally prefer oral administration compared to subcutaneous therapy. (Mahr et al., 2007; 
Canonica et al., 2003) Concerns and dilemmas still remain in relation to the optimal dose 
and treatment protocol . In addition, there are no standardized code for administration of 
SLIT therapy. Studies are underway to evaluate an FDA-approved product for SLIT. 
Hopefully these studies will assist clinicians in clarifying the role of SLIT therapy in the 
management of AR. (Cox et al., 2006; Hankin et al., 2010) 
There are many studies on clinical effectiveness of sublingual immunotherapy and we 
would like to point out one of the meta-analyses. Meta-analysis of SLIT for AR in children 
4–18 years of age involved 10 trials and 484 subjects. The results of this meta-analyses 
showed that SLIT was significantly more effective than placebo, by improving AR symptom 
scores and usage of rescue medication. Related to the possible, mainly local side effects it 
seems that SLIT is better tolerated than subcutaneous route of administration of allergen 
specific immunotherapy. Despite many clinical studies confirming the clinical efficacy there 
are still unmet needs for SLIT in children : the optimal dose and dosing frequency of 
allergen administration, time of administration of SLIT in patients unresponsive to 
pharmacotherapy, duration of SLIT, long-term efficacy, preventive capacity, other allergic 
processes beyond respiratory allergy, usage of SLIT in children in preschool ages etc. 
(Moingeon et al., 2006; Penagos et al., 2008) 
4. More about immunotherapy and sublingual immunotherapy in children 
The first data concerning immunotherapy dated from the beginning of 19th century. The 
main aim of the immunotherapy was to redirect inappropriate immunological response in 
atopic patients. It has proven to be efficacious to treat type I allergies to a variety of 
allergens. (Pichler et al., 2001; Moller et al., 2002) Since Food Drug Agency (FDA) reported 
more seriously adverse reaction post subcutaneous immunotherapy new routes of 
administration (sublingual and intranasal) have been widely considered. (Canonica et al., 
2003) After more than 500 million doses of SLIT administered to humans SLIT is proven to 
be much safer than subcutaneous immunotherapy (SCIT), with no evidence of anaphylactic 
shock recorded. (Wilson et al., 2003; Frew et al., 2001; Agostinis et al., 2005; et al., 2002) SLIT 
was firstly accepted as a viable alternative to SCIT in the World Health Organization (WHO) 
position paper, published in 1998, and then included in the ARIA guidelines. (Sub-Lingual 
Immunotherapy World Allergy Organization Position Paper 2009) The main targets for 
using SLIT are patients of all ages with good correlation between clinical symptoms of 
allergy and positive allergen specific IgE. Monosenzitized patients are the best candidates 
for SLIT. Recent studies have investigated using SLIT for the patients with food allergy, 
latex allergy, atopic dermatitis and allergy on insect venoms. (Sub-Lingual Immunotherapy 






uncontrolled with optimal pharmacotherapy (SCUAD), patients in whom pharmacotherapy 
induces undesirable side effects, patients refusing injections, patients who do not want to be 
on constant or long-term pharmacotherapy. (Sub-Lingual Immunotherapy World Allergy 
Organization Position Paper, 2009). 
Allergens using in SLIT persist in tablets and drops forms. (Casale , 2004) The most frequent 
schedule for using SLIT considers induction (build up) and retention phases. The best time 
for starting SLIT is 4/5 months before pollen season. (Allergy and Immunology Society of 
Serbia and Montenegro, Position Paper, 2005). 
 Optimal allergen extracts dose is a dose which is sufficient for improving clinical symptoms 
in a great number of patients without adverse reaction. (Moingeon et al., 2006). Despite 
excellent clinical experience in using SLIT the exact immunological mechanism is still 
undefined. The central paradigm for successful immunotherapy has been to reorient the 
pattern of allergen-specific T-cell responses in atopic patients from a Th2 to Th1 profile. 
There is currently a growing interest in eliciting regulatory T cells, capable of down 
regulating both Th1 and Th2 responses through the production of interleukin (IL)-10 and/or 
transforming growth factor (TGF)-ǃ. SLIT induces three categories of immunological 
changes: modulation of allergen-specific antibody responses; reduction in recruitment and 
activation of proinflammatory cells and changes in the pattern of allergen specific T-cell 
responses. 
5. Modulation of allergen-specific antibody responses 
SLIT was shown to increase allergen-specific IgG4 levels compared with placebo, with a 
more limited impact on specific IgE responses. A decrease in the IgE/IgG4 ratio has been 
observed in a number of SLIT studies (Bahceciler et al., 2005), with some exceptions. 
(Rolinck-Werninghaus et al., 2005). 
A meta analysis of six SLIT studies with detailed analysis of antibody responses concluded 
on a consistent increase in allergen-specific IgG4 levels. (Torres Lima et al., 2002) Such 
changes in the IgE/IgG4 ratio were found to correlate with a decrease in the late-phase skin 
reaction to the allergen and with the overall clinical efficacy of the vaccine in some studies 
(Torres Lima et al., 2002). In a recent phase I/II trial with grass pollen tablets, SLIT was 
shown to elicit allergen-specific seric IgAs in a dose-dependent fashion (Malling et al., 2005) 
and a small up regulation of IgA responses was also observed when SLIT was used in house 
dust mite allergic patients. Altogether, allergen-specific IgG (and IgA) antibodies induced 
by immunotherapy are thought to contribute to the positive clinical response through 
distinct and nonexclusive mechanisms: these antibodies can compete with IgEs for binding 
to the allergen, thereby preventing both basophil or mastocyte deregulation (Mothes et al., 
2003; Niederberger et al., 2004), as well as allergen capture and presentation to T 
lymphocytes by FcεRI+ and CD23+ antigen-presenting cells (APCs). and such antibodies 
may act as blocking antibodies by engaging low-affinity Fc receptors for immunoglobulins 
(e.g. FcǄRII) expressed by B lymphocytes, basophils, or mast cells. FcǄRII receptors contain 
immunoreceptor tyrosine-based inhibitory motifs (ITIM), they transduce, as a consequence, 
negative signals preventing cellular activation and release of soluble pro-inflammatory 
mediators following co-aggregation with FcεRI receptors. (Wachholz et al., 2003; Flicker et 
al., 2003) SLIT prevented the recruitment of eosinophils in the eyes or in the nose after 
allergen challenge. (Marcucci et al., 2001; Marcucci et al., 2003; Silvestri et al., 2002) SLIT 
with grass pollen extracts was shown to decrease local or systemic levels of eosinophil 
cationic protein (ECP), without any increase in tryptase. ( Marcucci et al., 2001). 
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Changes in the pattern of allergen specific T-cell responses. Recent studies focused on the 
impact of SLIT on CD4+ T cells responses. It is well known that allergic patients usually 
mount strong allergen-specific Th2 cells immune response, characterized by the secretion of 
high amounts of interleukin IL-4, IL-5 and IL-13 cytokines. 
(El Biaze et al., 2003). Concerning that a central goal for immunotherapy has been to reorient 
allergen specific T-cell responses in atopic patients from a Th2 to Th1 profile [the latter being 
rather associated with the production of interferon (IFN)-Ǆ and IL-12cytokines]. (Laaksonen 
et al., 2003; et al., Gabrielsson et al., 2001; et al., 2001; Faith et al., 2003; Oldfield et al., 2002;) 
Comparing with SCIT there is a less evidence on the impact of SLIT on T-cell responses. In 
several studies conducted in children or adults with seasonal allergic rhinoconjunctivitis to 
grass pollen, no significant effect of SLIT on T-cell functions (i.e. cytokine production, 
proliferation) was observed. (Rolinck-Werninghaus et al., 2005; Torres Lima et al., 2002) 
SLIT does not induce any detectable changes in the numbers of dendritic cells (DCs) nor T 
lymphocytes in the epithelium or lamina propria of the oral mucosa. Immunization through 
the sublingual route was nevertheless shown in other studies to decrease the production of 
the Th2 cytokine IL-13 and the proliferation of peripheral blood mononuclear cells (PBMCs) 
from patients allergic to house dust mite. (Ippoliti et al., 2003; Fenoglio et al., 2005) As of 
today, there is still no firm evidence that SLIT can induce regulatory T cells. A preliminary 
study suggests that SLIT increases IL-10 production in PBMCs from house dust mite (HDM) 
allergic patients following in vitro stimulation with Dermatophagoides farinae antigens, but 
also with recall antigens (e.g. Candida albicans) or PHA, when compared with untreated 
allergic patients. (Ciprandi et al. 2005) Thе fact that some IL-10-secreting T cells are not 
allergen-specific raises the possibility of a bystander immunosuppressive effect of SLIT. Of 
note, high-dose SLIT regimens with ovalbumin in mice induce specific T cells producing 
TGF-ǃ in the spleen of sensitized animals. 
6. Regulatory T cells and allergy vaccines 
Although both anergy and T-cell depletion are known to contribute to the establishment of 
peripheral tolerance against environmental antigens, it is now broadly admitted that 
antigen-specific T-cell populations with suppressive/regulatory function play a key role in 
controlling immune responses to both self- and nonself-antigens. (Blaser et al., 2004; Umetsu 
et al., 2003; Jonuleit et al., 2003; Hawrylowicz et al.,2005) These cells, termed regulatory T 
cells, are heterogeneous, and include both: (i) naturally occurring CD4+CD25+ T cells and 
(ii) cells induced in the periphery following antigen exposure (e.g. Tr1 cells, Th3 cells, and 
CD8+ regulatory T cells). There is a growing evidence supporting the role of regulatory T 
cells in controlling the development of asthma and allergic disease in a variety of models , 
although it is not clear yet which of the various regulatory T cell subsets are the most 
important in this regard. (Taylor et al., 2004) A revised version of the hygiene hypothesis 
proposes that a limited exposure to infectious pathogens during infancy, most particularly 
telluric mycobacteria and parasites, may prevent the establishment of not only a Th1, but 
also a T reg repertoire, thereby explaining in part the observed increase in prevalence of 
allergies in developed countries. (Yazdanbakhsh et al., 2002) 
Several studies documented an association between atopy and a defect in T reg functions. 
For example, children born with a dysfunctional Fox p3 gene presented with a deficit in 
CD4+CD25+ regulatory T cells, develop severe autoimmune diseases often associated with 






enteropathy, and X-linked inheritance (IPEX) syndrome]. (Gambineri et al., 2003) Moreover, 
for at least some atopic subjects with active disease, the suppressive activity of CD4+CD25+ 
regulatory T cells is significantly decreased in vitro when compared with nonatopic 
individuals, potentially explaining the loss of tolerance against allergens. (Ling et al., 2004) 
Studies showed that DCs from children with allergic rhinitis can be impaired in their 
capacity to produce IL-10. (Grindebacke et al., 2004) Interestingly, allergen-specific IL-10-
secreting Tr1 cells are highly represented in healthy individuals in comparison with 
allergen-specific IL-4-secreting Th2 cells, suggesting that regulatory T cells are predominant 
during natural immune responses to environmental allergens in nonatopic donors. (Gentile 
et al., 2004; Akdis et al., 2004) Regulatory T lymphocytes can control an established allergic 
response via distinct mechanisms: IL-10 and TGF-ǃ decrease IgE production and enhance 
IgG4 and IgA production, respectively. Both cytokines lower the release of proinflammatory 
mediators by downregulating IgE-dependent activation of basophils and mast cells and by 
decreasing survival and activation of eosinophils. IL-10 and TGF-ǃ also inhibit the 
production of Th2 cytokines such as IL-4 and IL-5. (Akdis et al., 2004;, Blaser et al., 2004; 
Akdis et al., 2001) In addition, regulatory T cells exhibit a direct inhibitory effect on Th1 and 
Th2 T cells, through cell–cell contact, or by decreasing the antigen presenting function of DCs. 
Regulatory T cells producing IL-10 and/or TGF-b are induced not only in atopic patients by 
successful immunotherapy, but also during natural allergen exposure in healthy people. As 
per the hygiene hypothesis, limited exposure to bacteria and parasites in developed 
countries may result in a poor establishment of a T reg repertoire during childhood, thereby 
contributing to an increase in the frequency of allergies. Regulatory T cells can control and 
regulate all effectors mechanisms activated during allergy and Th2 responses through the 
production of IL-10/TGF- ǃ and/or cell–cell contact. IL-10 is a potent suppressor of total 
and allergen-specific IgEs, whereas it induces an antibody isotype switch towards IgG4. 
TGF-ǃ also decreases IgE production and induces immunoglobulin isotype switch towards 
IgA. IL-10 and TGF- ǃ act directly or indirectly on human airways to decrease both mucus 
production and airway hyper-reactivity. 
7. Oral mucosa and immune responses 
7.1 SLIT and induction of peripheral tolerance 
Sublingual immunotherapy takes advantage of an important physiological mechanism (i.e. 
oral tolerance), which has been evolutionarily conserved to ensure immune tolerance to 
various antigenic stimuli from the environment, especially from food and commensal 
bacteria. During SLIT, as for immunization at any mucosal surface, the allergen is captured 
locally (i.e. within the oral mucosa) by Langerhans-like DCs following either phagocytosis, 
macropinocytosis or receptor-mediated endocytosis. Subsequent to allergen capture, DCs 
mature and migrate to proximal draining lymph nodes (e.g. submaxillary, superficial 
cervical and internal jugular), as a consequence of changes in expression of surface receptors 
(e.g. the CCR7 chemokine receptor) involved in adhesion and trafficking. Those lymph 
nodes represent specialized microenvironments favoring the induction of mucosal tolerance 
through the production of blocking IgG antibodies (IgG2b in mice) and the induction of T 
lymphocytes with suppressive function. (Van Helvoort et al., 2004) Importantly, the 
magnitude of CD4+ T-cell responses elicited within lymph nodes is directly proportional to 
the number of allergen carrying DCs that migrate to lymph nodes, which clearly represents 
a limiting step. (Martin-Fotecha et al., 2003) Eventually, as a consequence of the circulation 
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of allergen-specific activated effector T cells throughout the body and the persistence of 
memory cells, a local (i.e. sublingual) administration of the allergen during desensitization 
results in both systemic and mucosal protective immune responses. Dendritic cells in the 
sublingual mucosa exhibit morphological characteristics of Langerhans cells, including the 
presence of intracytoplasmic Birbeck granules. (Allam et al., 2003) Interestingly, 
Langerhans-like cells from the oral mucosa constitutively express both low- (CD23) and 
high- (FCeRI) affinity receptors for IgEs, which may facilitate IgE-mediated allergen capture 
in atopic individuals. (Allam et al., 2003) Perhaps, more importantly, upon engagement of 
such IgE receptors, oral Langerhans-like cells produce IL-10, TGFb and up regulate 
indoleamine 2-dioxygenase (IDO), a rate-limiting enzyme-metabolizing tryptophan, thereby 
resulting in a decrease in T-cell proliferation. (Allam et al., 2003; Von Bubnoff et al., 2004) As 
discussed above, there is still no formal evidence of Treg induction via the sublingual route. 
Nevertheless, on the basis of its aforementioned characteristics, the immune system in the 
oral mucosa appears prone to induce active tolerance mechanisms against allergens and 
antigens from the environment. Consistent with this, there is preliminary evidence that SLIT 
elicits IL-10-producing T cells in humans (Ciprandi et al., 2005) and antigen-specific TGF-b+ 
T cells in murine. (Moingeon, et al., 2004). 
8. Clinical efficacy 
Usually clinical efficacy of SLIT is measured by the Rhinoconjunctivitis Total Symptom 
Score (RTSS), which included the 6 most common symptoms of pollinosis (sneezing, 
rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus, and watery eyes). A score 
ranging from 0 to 3, according to the Center for Drug Evaluation and Research guidance 
(April 2000), was used for each individual symptom: 0/5 no symptoms, 1/5 mild symptoms 
(symptoms clearly present, but minimal awareness; easily tolerated), 2/5 moderate 
symptoms (definite awareness of bothersome but tolerable symptoms), and 3/5 severe 
symptoms (symptoms hard to tolerate and/or cause interference with activities of daily 
living and/or sleeping). 
From approximately a month before and during the pollen season, patients completed a 
daily diary card to score nasal and ocular symptoms using the RTSS. The average RTSS was 
calculated during the entire pollen season. In addition, the effect of immunotherapy on the 6 
individual symptom scores (sneezing, runny nose, itchy nose, nasal congestion,watery eyes, 
and itchy eyes) was analyzed as secondary outcomes. The proportion of symptom-free days 
(%) during the pollen season was also assessed. A symptom-free day was a day on 
which‘‘0/ 5 absent’’ was recorded for each of the 6 individual rhinoconjunctivitis symptoms. 
Allergen specific immunotherapy (ASIT) is very important in pediatric population. It has 
been shown to have possibility to change natural course of allergic diseases and to prevent 
new sensibilisation. ASIT is the only therapeutic method with causal effects in children 
population. Sublingual route of allergen administration is very comfortable, simple and 
non-traumatic especially for children. 
The first evidence of the effect of SLIT in children came from an 18-month study of 2 
different doses of SLIT for tree-pollen allergy in 88 children suffering seasonal allergic 
rhinitis, confirmed by skin prick test, specific serum IgE, and conjunctival allergen 
challenge. Eighteen months of SLIT with tree pollen extract provided dose-dependent 
benefits in terms of significantly reduced symptoms and medication use.(Valovirta E et al., 






randomized controlled trial (RCTs) have now been published, both showing a clear effect of 
allergen tablets in childhood. A statistically significant reduction in rhinitis symptoms (28%) 
and medication (64%) score was shown during the pollen season in 114 children receiving 
active grass allergen tablets (with 15g Phl p 5) compared with 120 children in the placebo 
group.( Wahn U et al., 2009). The other DBPC/RCT evaluated the efficacy of 5-grass tablets 
(with 25g group 5 major allergen) administered pre- and coseasonally to 227 children with 
seasonal allergic rhino-conjunctivitis. In those receiving the 5-grass tablets a significant 
improvement was found in symptom and medication scores.( Roder E et al., 2007) All these 
studies, clearly show the efficacy of SLIT in reducing the symptom score during pollen 
season in children with rhinitis; furthermore, there were also a significant reduction in 
medication use. The allergens that have been used with success in SLIT in the pediatric age 
group for rhinitis are pollen from Phleum pratense, 5-grass mix, Parietaria and Betulaceae 
pollens and HDM. SLIT with olive pollen showed only improvement in symptoms and one 
grass study was negative.( Bufe A et al. 2004) 
23 DBPC studies in the period of 1990-2002. documented clinical efficacy of SLIT. Pediatric 
population was involved in 16 of those studies. SLIT has been shown to reduce bronchial 
hyperreactivity, symptoms and medication scores in adolescents population treated with 
SLIT containing extracts of grass pollen. (Robinson et al., 2004) 
9. Safety in children 
The sublingual route was introduced with the aim of reducing side effects and increasing the 
safety of immunotherapy. Recent studies showed that there is no difference in the incidence of 
adverse events (AE) between children and adults ( Passalacqua G, et al., 2007) and SLIT has 
been shown to be safe. The most frequently reported AEs (mostly self-limiting) are local in the 
oral mucosa (itching and swelling) and of the digestive system. Just a few cases were 
considered moderate/severe requiring medical intervention. Experience must be gained in the 
use of single versus multiple-allergens. SLIT with a single allergen is the most common 
practice in Europe whereas multiple allergens are used mainly in USA, Latin America and 
some other parts of the world. In adults, in one study, use of SLIT with multiple allergens was 
reported to be as safe as SLIT with a single allergen.( Agostinis F et al., 2008) 
It is also very important to mention that there are three studies, 2 observational and one 
postmarketing survey, specifically designed to assess the safety of SLIT in young children. A 
total of 231 children younger than 5-years-old, who were treated with various pollen and mite 
allergens (33 patients received allergoid) were included.( Agostini et al, 2005; Fiocchi A,et al. , 
2005; Rienzo VD et al. , 2005) AEs were reported in 5 to 15% of patients in a total of 68,975 
doses with rates of 0.268, 0.766, and 1.767 AEs per 1,000 doses in the 3 studies. Most reactions 
appeared to be mild or moderate and resolved without treatment. Dose reduction by changing 
from a sublingual-swallow to a sublingual-spit method controlled gastrointestinal reactions in 
one study. One further RCT with HDM SLIT in 138 children aged 2–5 years with asthma or 
rhinitis showed only mild to moderate local AEs. (Rodriguez-Santos O. Et al., 2008) 
10. Our clinical experience 
In our practice, we have started using the allergen specific immunotherapy in children more 
than 10 years ago, however, more frequently for the last 4 to 5 years. Number of children on 
SLIT is 37, but 31 successfully followed the protocol. The data about the patients, their 
outcomes and clinical results are about to be analyzed in another article. The youngest child 
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on SLIT is 7 years old, and the upper age limit doesn’t exist. The adolescent patients started 
at 17 years of age continue the treatment after their pediatric ages. Patients sensitized with 
Dermatophagoides pteronyssinus are the most frequent cases for SLIT, slightly less frequent 
is the group of patients sensitized with ragweed pollen (Ambrosia elatior or Artemisia). 
Predominantly, current symptoms are allergic rhinitis, allergic rhinoconjuncitivitis (hay 
fever), and 70% of all patients claimed asthma symptoms in the early childhood. At the 
moment of inclusion to a group for SLIT, asthmatic symptoms were mild or absent. Couple 
of patients stopped the SLIT from their own reasons, and 2 of the patients had to follow 
protocol with reduced maintenance doses due to the adverse reactions (sneezing, coughing, 
tickling of the throat). The final results and outcomes will be announced and published 
elsewhere, but we have sufficient data to state: good clinical efficacy, lack of hay fever 
symptoms or diminishing the symptoms after 3 years of therapeutic regime, satisfaction 
with collaboration and treatment adherence, valuable improvement of patients and their 
families’ quality of life. (Z. Zivkovic: personal communication) 
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